• The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy.

      Treacy, Maxwell P; Hurst, Tara P; Royal Victoria Eye and Ear Hospital, Adelaide Road, Dublin 2, Dublin, Ireland. max@treacy.ie (2012-09)
      Systemic therapeutics targeting the peroxisome proliferator-activated receptors have been found to be beneficial in the treatment of diabetic retinopathy. In this paper, we provide a rationale for the use of these therapeutics as intraocular agents. In addition, we introduce the peroxisome proliferator-activated receptors and describe their functions in response to the drugs.